BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23947828)

  • 1. Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis.
    Schiffmann L; Klautke G; Wedermann N; Gock M; Prall F; Fietkau R; Rau B; Klar E
    BMC Cancer; 2013 Aug; 13():388. PubMed ID: 23947828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.
    Schiffmann L; Wedermann N; Gock M; Prall F; Klautke G; Fietkau R; Rau B; Klar E
    BMC Surg; 2013 Sep; 13():43. PubMed ID: 24073705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
    Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
    Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of adjuvant chemotherapy after neoadjuvant radio- or radiochemotherapy for patients with locally advanced rectal cancer.
    Lichthardt S; Zenorini L; Wagner J; Baur J; Kerscher A; Matthes N; Kastner C; Pelz J; Kunzmann V; Germer CT; Wiegering A
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2363-2373. PubMed ID: 28756493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?
    São Julião GP; Habr-Gama A; Vailati BB; Aguilar PB; Sabbaga J; Araújo SEA; Mattacheo A; Alexandre FA; Fernandez LM; Gomes DB; Gama-Rodrigues J; Perez RO
    Eur J Surg Oncol; 2018 Jan; 44(1):93-99. PubMed ID: 29217398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers.
    Rades D; Vogelsang RP; Treder M; Janssen S; Schild SE; Holländer NH; Gögenur I
    Anticancer Res; 2018 Dec; 38(12):6877-6880. PubMed ID: 30504404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The postoperative adjuvant radiation therapy and radiochemotherapy for UICC stage II and III rectal cancer. A retrospective analysis.
    Bagatzounis A; Willner J; Oppitz U; Flentje M
    Strahlenther Onkol; 2000 Mar; 176(3):112-7. PubMed ID: 10742831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lymph node dissection after primary surgery and neoadjuvant radiochemotherapy of rectal cancer. Interim analysis of a multicenter prospective observational study (OCUM)].
    Kreis ME; Maurer CA; Ruppert R; Ptok H; Strassburg J; Junginger T; Merkel S; Hermanek P
    Chirurg; 2015 Dec; 86(12):1132-7. PubMed ID: 26223668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.
    Park IJ; You YN; Skibber JM; Rodriguez-Bigas MA; Feig B; Nguyen S; Hu CY; Chang GJ
    Dis Colon Rectum; 2013 Feb; 56(2):135-41. PubMed ID: 23303140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term results and long-term oncologic outcomes between neoadjuvant chemoradiotherapy and adjuvant postoperative chemoradiotherapy for stage III rectal cancer: a case-matched study.
    Kang J; Jang SM; Baek JH; Lee WS; Cho TH
    Ann Surg Oncol; 2012 Aug; 19(8):2494-9. PubMed ID: 22476817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Node Negative, Pathologically Node Positive Rectal Cancer Patients Who Did Not Receive Neoadjuvant Therapy.
    Akeel N; Lan N; Stocchi L; Costedio MM; Dietz DW; Gorgun E; Kalady MF; Karagkounis G; Kessler H; Remzi FH
    J Gastrointest Surg; 2017 Jan; 21(1):49-55. PubMed ID: 27796635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rectal cancer: current status of multimodal therapy--when and how?].
    Gaedcke J; Liersch T; Hess C; Becker H; Rödel C; Ghadimi BM
    Zentralbl Chir; 2011 Aug; 136(4):334-42. PubMed ID: 21863511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
    Renehan AG; Malcomson L; Emsley R; Gollins S; Maw A; Myint AS; Rooney PS; Susnerwala S; Blower A; Saunders MP; Wilson MS; Scott N; O'Dwyer ST
    Lancet Oncol; 2016 Feb; 17(2):174-183. PubMed ID: 26705854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
    Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
    BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total neoadjuvant treatment of locally advanced rectal cancer with high risk factors in Slovenia.
    Tuta M; Boc N; Brecelj E; Omejc M; Anderluh F; Ermenc AS; Peressutti AJ; Oblak I; Krebs B; Velenik V
    Radiol Oncol; 2019 Oct; 53(4):465-472. PubMed ID: 31652124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital.
    Yeung WW; Ma BB; Lee JF; Ng SS; Cheung MH; Ho WM; Tsang MW; Chu S; Lam DC; Mo FK
    Hong Kong Med J; 2016 Dec; 22(6):546-55. PubMed ID: 27795447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.